首页> 中文期刊> 《实用临床医药杂志》 >下调miR-126对大鼠降血压作用的实验研究

下调miR-126对大鼠降血压作用的实验研究

         

摘要

Objective To explore whether miR -126 can be used as a new therapeutic target in primary hypertension. Methods Twenty - four spontaneously hypertensive rats (SHR) were randomly divided into 4 groups. The systolic blood pressure,diastolic pressure,mean arterial pressure and heart rate were collected weekly. After 8 weeks of virus administration,the heart,kidney,brain,liver,lung tissues were made to frozen section,and the distribution of lentiviral vectors in different tissue was observed by fluorescence microscope. ELISA kit was used to determine the serum nitric oxide (NO) content. Results There was no significant antihypertensive effect when miR - 126 was down regulated to treat primary hypertension. Conclusion There is no significant effect on the decrease of blood pressure when miR - 126 is down regulated in the treatment of primary hypertension. The increased level of miR - 126 expression in hypertensive patients may be due to a compensatory mechanism. However,further research still needs to be done.%目的 探讨原发性高血压中miR-126是否可作为一种新的治疗靶点.方法 24只自发性高血压大鼠(SHR)随机分为4组,每周测量收缩压、舒张压、平均动脉压及心率.经过8周的病毒载体转染的处理,心、肾、脑、肝、肺组织被制成冰冻切片,通过荧光显微镜观察慢病毒载体在各个组织中的分布.应用ELISA试剂盒来测定血清NO含量.结果 大鼠中下调miR-126无明显降血压的作用.结论 通过下调miR-126来治疗原发性高血压并没有显著降血压的作用.高血压患者中miR-126表达的增加可能是由于一种代偿机制,具体机制有待进一步的研究.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号